TY-9591 plus chemo for first-line EGFR-mutant lung cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new targeted drug (TY-9591) combined with chemotherapy as a first treatment for people with advanced non-small cell lung cancer that has a specific EGFR mutation. It may offer a more effective option for those who haven't had prior therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 and under 80 years old.
- You have advanced non-squamous non-small cell lung cancer with an EGFR mutation (like exon 19 deletion or L858R).
- You have not had any prior treatment for advanced or metastatic lung cancer.
- Your cancer has at least one measurable tumor that hasn't been treated with radiation.
- You are in good enough health to carry out daily activities (ECOG score 0 or 1).
- Your blood counts, liver, and kidney function are within acceptable limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies TY-9591 in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has specific EGFR gene changes. It’s for those who haven’t had earlier medicines for advanced lung cancer, and it aims to see if the drug works better or safer than the comparison treatment.
This phase 2 trial studies TY-9591 in people with advanced non-small cell lung cancer (NSCLC) that has spread to the brain and has specific EGFR mutations. It aims to see whether the medicine can control the cancer in the brain and the rest of the body, without needing immediate brain radiation.
This trial studies how well targeted therapy works for advanced non-small cell lung cancer (NSCLC) that has spread. You may qualify if you have a specific gene change and are starting your first targeted treatment.
This trial tests YK-029A as the first anti-cancer treatment instead of standard platinum chemotherapy for certain advanced non-small cell lung cancers with an EGFR exon 20 insertion mutation. It may help shrink or control tumors while improving how patients tolerate treatment.
This trial compares a new targeted therapy pill (firmanertinib) to standard chemotherapy in people with advanced non-small cell lung cancer whose tumors have a specific EGFR mutation (PACC or L861Q). If you haven't had treatment for advanced disease and your cancer matches these mutations, this study may offer a more convenient oral option.
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.